AIMS: The aim of the study was to estimate the prevalence of and risk factors for non-sentinel node (NSN) involvement in breast cancer patients with sentinel node (SN) micrometastases. METHODS: Eighty-four patients with SN micrometastases were included. Both the SN and NSN were examined using serial sectioning and immunohistohemistry. Various indices were evaluated as possible risk factors for NSN involvement. RESULTS: NSN involvement was found in 22/84 patients. The median size of the NSN metastases was 1.25 mm (0.01-12 mm). The NSN metastases were larger than 2 mm in 8 patients and smaller than 0.2 mm in 6 patients. NSN involvement was observed in 14/35 patients with metastatic findings in all removed SN. Three of the 23 patients with 2 or 3 tumour negative SN had NSN metastases. None of the 12 patients with 4 or more uninvolved SN had NSN metastases. NSN involvement could not excluded by other patient, tumour or sentinel node related factors. CONCLUSIONS: Every fourth patient will have residual disease in the axilla, 10% even large metastases, if axillary clearance is omitted in patients with SN micrometastases. The risk of NSN involvement seems negligible in patients with a single SN micrometastasis and four or more healthy SN harvested.
AIMS: The aim of the study was to estimate the prevalence of and risk factors for non-sentinel node (NSN) involvement in breast cancerpatients with sentinel node (SN) micrometastases. METHODS: Eighty-four patients with SN micrometastases were included. Both the SN and NSN were examined using serial sectioning and immunohistohemistry. Various indices were evaluated as possible risk factors for NSN involvement. RESULTS: NSN involvement was found in 22/84 patients. The median size of the NSN metastases was 1.25 mm (0.01-12 mm). The NSN metastases were larger than 2 mm in 8 patients and smaller than 0.2 mm in 6 patients. NSN involvement was observed in 14/35 patients with metastatic findings in all removed SN. Three of the 23 patients with 2 or 3 tumour negative SN had NSN metastases. None of the 12 patients with 4 or more uninvolved SN had NSN metastases. NSN involvement could not excluded by other patient, tumour or sentinel node related factors. CONCLUSIONS: Every fourth patient will have residual disease in the axilla, 10% even large metastases, if axillary clearance is omitted in patients with SN micrometastases. The risk of NSN involvement seems negligible in patients with a single SN micrometastasis and four or more healthy SN harvested.
Authors: Johannes Bargehr; Michael Edlinger; Michael Hubalek; Christian Marth; Roland Reitsamer Journal: Breast Care (Basel) Date: 2013-06 Impact factor: 2.860
Authors: P Carcoforo; U Maestroni; P Querzoli; S Lanzara; K Maravegias; L Feggi; G Soliani; E Basaglia Journal: World J Surg Date: 2006-09 Impact factor: 3.352
Authors: Carolien H M van Deurzen; Maaike de Boer; Evelyn M Monninkhof; Peter Bult; Elsken van der Wall; Vivianne C G Tjan-Heijnen; Paul J van Diest Journal: J Natl Cancer Inst Date: 2008-11-11 Impact factor: 13.506
Authors: Jenni S Liikanen; Marjut H Leidenius; Heikki Joensuu; Jaana H Vironen; Tuomo J Meretoja Journal: Br J Cancer Date: 2018-04-24 Impact factor: 7.640
Authors: Anna V Britto; André A Schenka; Natália G Moraes-Schenka; Marcelo Alvarenga; Júlia Y Shinzato; José Vassallo; Laura S Ward Journal: BMC Cancer Date: 2009-04-08 Impact factor: 4.430